halofuginone has been researched along with Lung Adenocarcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baird, L; Miyata, K; Naito, M; Panda, H; Saito, R; Suzuki, M; Uruno, A; Wen, H; Yamamoto, M | 1 |
1 other study(ies) available for halofuginone and Lung Adenocarcinoma
| Article | Year |
|---|---|
Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity.
Topics: Adenocarcinoma of Lung; Chromatography, Liquid; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Micelles; Nanoparticles; NF-E2-Related Factor 2; Oxidative Stress; Piperidines; Quinazolinones; Tandem Mass Spectrometry | 2022 |